Cargando…

International Physicians Delphi Survey: Managing Patients With IgA Nephropathy

Detalles Bibliográficos
Autores principales:	Floege, Jürgen, Barratt, Jonathan, Coppo, Rosanna, Lafayette, Richard, Radhakrishnan, Jai, Reich, Heather N., Rovin, Brad H., Selewski, David T., Vivarelli, Marina, Pham, Christopher, Tesař, Vladimír
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458983/ https://www.ncbi.nlm.nih.gov/pubmed/36090484 http://dx.doi.org/10.1016/j.ekir.2022.05.022

Ejemplares similares

Why Target the Gut to Treat IgA Nephropathy?
por: Barratt, Jonathan, et al.
Publicado: (2020)

Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy
por: Lafayette, Richard A., et al.
Publicado: (2020)

Challenges in IgA Nephropathy Management: An Era of Complement Inhibition
por: Tesař, Vladimir, et al.
Publicado: (2023)

IgA nephropathy: a perspective for 2021
por: Floege, Jürgen, et al.
Publicado: (2021)

The mucosal immune system and IgA nephropathy
por: Gesualdo, Loreto, et al.
Publicado: (2021)

Current treatment of IgA nephropathy
por: Floege, Jürgen, et al.
Publicado: (2021)

Crescents and IgA Nephropathy: A Delicate Marriage
por: Trimarchi, Hernán, et al.
Publicado: (2022)

Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)
por: Barratt, Jonathan, et al.
Publicado: (2019)

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
por: Barratt, Jonathan, et al.
Publicado: (2023)

The incidence and prevalence of IgA nephropathy in Europe
por: Willey, Cynthia J, et al.
Publicado: (2023)

Emerging Modes of Treatment of IgA Nephropathy
por: Maixnerova, Dita, et al.
Publicado: (2020)

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
por: Rizk, Dana V., et al.
Publicado: (2023)

Expanding options of supportive care in IgA nephropathy
por: Maixnerova, Dita, et al.
Publicado: (2023)

Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy
por: Negrea, Lavinia, et al.
Publicado: (2021)

Noninvasive Urinary Monitoring of Progression in IgA Nephropathy
por: Yang, Joshua Y. C., et al.
Publicado: (2019)

New insights into the pathogenesis of IgA nephropathy
por: Yeo, See Cheng, et al.
Publicado: (2017)

pSTAT1 Is Activated during the Progression of IgA Nephropathy
por: Tao, Jianling, et al.
Publicado: (2022)

Diagnosis and Treatment of Patients With Focal Segmental Glomerulosclerosis/Steroid-Resistant Nephrotic Syndrome: A Delphi Survey
por: Floege, Jürgen, et al.
Publicado: (2022)

IgA Nephropathy Genetic Risk Score to Estimate the Prevalence of IgA Nephropathy in UK Biobank
por: Sukcharoen, Kittiya, et al.
Publicado: (2020)

The coincidence of IgA nephropathy and Fabry disease
por: Maixnerová, Dita, et al.
Publicado: (2013)

Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments
por: Coppo, Rosanna, et al.
Publicado: (2014)

New strategies and perspectives on managing IgA nephropathy
por: Selvaskandan, Haresh, et al.
Publicado: (2019)

Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression
por: Maixnerova, Dita, et al.
Publicado: (2019)

Correction: Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression
por: Maixnerova, Dita, et al.
Publicado: (2019)

Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy
por: Lennartz, David Paul, et al.
Publicado: (2020)

Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy
por: Kim, Min Jeong, et al.
Publicado: (2016)

Intestinal permeability in patients with IgA nephropathy and other glomerular diseases: an observational study
por: Seikrit, Claudia, et al.
Publicado: (2022)

The Role of IgA in the Pathogenesis of IgA Nephropathy
por: Perše, Martina, et al.
Publicado: (2019)

New Insights into the Pathogenesis and Treatment Strategies in IgA Nephropathy
por: Scionti, Katrin, et al.
Publicado: (2021)

Targeting the Endothelin A Receptor in IgA Nephropathy
por: Kohan, Donald E., et al.
Publicado: (2023)

An Update on the Current State of Management and Clinical Trials for IgA Nephropathy
por: Cheung, Chee Kay, et al.
Publicado: (2021)

Global Incidence of IgA Nephropathy by Race and Ethnicity: A Systematic Review
por: Kiryluk, Krzysztof, et al.
Publicado: (2023)

IgA Vasculitis and IgA Nephropathy: Same Disease?
por: Pillebout, Evangeline
Publicado: (2021)

Urine proteomics for prediction of disease progression in patients with IgA nephropathy
por: Rudnicki, Michael, et al.
Publicado: (2020)

Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management
por: Selvaskandan, Haresh, et al.
Publicado: (2020)

Experimental IgA nephropathy
Publicado: (1979)

Sulodexide in IgA nephropathy
Publicado: (2013)

T lymphocytes in IgA nephropathy
por: Tang, Yuyan, et al.
Publicado: (2020)

The Non-Coding RNA Landscape in IgA Nephropathy—Where Are We in 2021?
por: Pawluczyk, Izabella Z. A., et al.
Publicado: (2021)

Secondary IgA Nephropathy Shares the Same Immune Features With Primary IgA Nephropathy
por: Wang, Manliu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l848t87long7puo4tnsijq0afd